Replacing two chemo cycles with blinatumomab raised survival in childhood leukaemia

In children with newly diagnosed high-risk B-cell acute lymphoblastic leukaemia, replacing two cycles of intensive chemotherapy with two cycles of the antibody blinatumomab raised the share alive and free of leukaemia at four years to 83.0%, from 70.3% with chemotherapy [s1]. It did so while causing far fewer treatment-related infections, according to an interim analysis of a randomised trial published in the New England Journal of Medicine on September 16 [s1].

Blinatumomab is a bispecific T-cell engager: one arm binds CD19, a protein on the surface of B cells, and the other binds CD3 on the patient's own T cells, drawing the two together so the immune system kills the leukaemic cell [s1]. The drug is already used in relapsed disease and to clear residual leukaemia. The question this trial asked is different and more consequential: whether it can stand in for part of the toxic chemotherapy that front-line treatment has long depended on.

The trial

Children with high-risk B-cell ALL were randomly assigned, in a 1:1 ratio, to receive two cycles of blinatumomab or two cycles of conventional chemotherapy after their initial consolidation phase [s1]. The primary end point was event-free survival, measured as the time from randomisation to the first of resistance to treatment, relapse, a second cancer, or death from any cause [s1]. The trial was designed to detect whether four-year event-free survival would be 10 percentage points higher in the blinatumomab group [s1].

Of 768 eligible patients, 709 (92.3%) underwent randomisation: 358 to blinatumomab and 351 to the control group [s1]. The results reported here come from a planned interim analysis at a median follow-up of 2.9 years [s1].

What it found

Estimated four-year event-free survival was 83.0% (95% confidence interval, 77.4 to 87.4) in the blinatumomab group and 70.3% (95% CI, 63.8 to 75.9) in the control group, a difference that was statistically significant in the intention-to-treat analysis (P=0.0002) [s1]. The estimated hazard ratio for a primary end-point event with blinatumomab versus chemotherapy was 0.51 (95% CI, 0.35 to 0.73) — roughly a halving of the risk of relapse, resistance, second cancer or death [s1].

The safety contrast was as striking as the efficacy one. Infection related to the trial treatment occurred in 23.9% of the blinatumomab group and in 69.4% of the chemotherapy group (P<0.001) [s1]. Life-threatening adverse events occurred in 2 patients (0.5%) given blinatumomab, including one (0.3%) that was fatal, against 16 patients (4.7%) in the control group [s1]. That is the core trade the antibody appears to offer in this setting: more leukaemia control with less of the collateral harm that makes intensive chemotherapy dangerous.

Blinatumomab is not free of its own toxicities. Neurotoxic events were reported in 12.0% of the blinatumomab group and in 3.2% of the control group (P<0.001), and cytokine release syndrome of grade 2 or higher — an immune over-activation that is a signature risk of T-cell-engaging therapy — occurred in 1.1% of blinatumomab recipients [s1].

The limits

This is an interim analysis, not the final word. With a median of 2.9 years of follow-up, the durability of the four-year estimates rests on relatively few children observed that far out, and longer follow-up could narrow or widen the gap [s1]. The finding applies specifically to children with high-risk B-cell ALL who had already completed consolidation; it does not speak to standard-risk disease or to other leukaemia subtypes [s1]. The trial was funded by Deutsche Krebshilfe and others, not by the drug's manufacturer, and is registered in the EU Clinical Trials system (EudraCT 2016-001935-12) [s1].

An accompanying editorial titled the antibody "a new standard of care" in ALL — a strong phrase in a field where front-line protocols change slowly and only on robust evidence [s2].

What to watch

The final analysis with mature follow-up will show whether the survival advantage holds and whether the sharply lower infection burden translates into fewer long-term complications. Also unsettled is how far the result generalises: the site has covered the parallel effort to replace toxic induction chemotherapy in adults with acute myeloid leukaemia, and the broader move toward immune cell therapies engineered to spare healthy tissue. The direction of travel in leukaemia treatment is toward doing more with targeted immunotherapy and less with cytotoxic drugs; this trial is one of the clearer demonstrations that the swap can work in children.

This article describes trial results, including a drug and its adverse events, for informational purposes only. It is not medical advice or a recommendation about any treatment.

Sources

• [s1] Schrappe M, et al. Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia. New England Journal of Medicine, published online 2026-09-16.
• [s2] Myers RM, Hunger SP. Blinatumomab — A New Standard of Care in Acute Lymphoblastic Leukemia. New England Journal of Medicine, published online 2026-09-16.